Outcome from surgical management of secretory pituitary adenomas in Christchurch, New Zealand.
BACKGROUND
Recent evidence has highlighted the importance of the neurosurgeon in the management of secretory pituitary tumours, but most reports are from major centres.


OBJECTIVE
To audit the surgical outcome of patients with acromegaly and Cushing's disease treated in a small centre (Christchurch, New Zealand) by a dedicated neurosurgeon with an interest in pituitary disease, and follow-up through an outpatient Department of Endocrinology.


METHODS
All cases of acromegaly and Cushing's disease admitted for surgery in Christchurch Hospital between 1984 and 2000 were audited. Data concerning preoperative findings, surgical remission rate, complications and follow-up were obtained from 44 patients (28 acromegaly, 16 Cushing's disease).


RESULTS
Of the 28 acromegalic patients, 14 patients (50%) had a mean growth hormone level <2.5 micro g/L within the first postoperative week. Of the 15 Cushing's disease patients in whom the pituitary fossa was explored, 13 patients (87%) entered a postoperative remission, defined as an 08.00 h cortisol <200 nmol/L (normal range 250-800 nmol/L). No perioperative deaths occurred. Two of the 43 patients (4.7%) developed permanent diabetes insipidus, while eight of the 28 patients who were operated on for acromegaly (29%) eventually required some replacement treatment for hypopituitarism during follow-up (one presented with apoplexy and seven were treated with postoperative radiotherapy).


CONCLUSIONS
In a small centre with a dedicated pituitary surgeon, operative remission rates approach those obtained in larger, more specialized centres. However, given New Zealand's small, but geographically spread population, consideration should be given to establishing one or two units for the surgical management of secretory pituitary adenomas.
Inder
W J
WJ
Department of Endocrinology, Christchurch Hospital, Christchurch, New Zealand. winder@medstv.unimelb.edu.au
Espiner
E A
EA
MacFarlane
M R
MR
D000172:Acromegaly / Q000378:metabolism / Q000601:surgery*; D000236:Adenoma / Q000378:metabolism / Q000601:surgery*; D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D003480:Cushing Syndrome / Q000378:metabolism / Q000601:surgery*; D005260:Female; D005500:Follow-Up Studies; D019382:Human Growth Hormone / Q000378:metabolism*; D006801:Humans; D008297:Male; D008875:Middle Aged; D019635:Neurosurgical Procedures / Q000379:methods*; D009520:New Zealand; D010903:Pituitary Gland, Anterior / Q000473:pathology / Q000601:surgery*; D010911:Pituitary Neoplasms / Q000378:metabolism / Q000601:surgery*; D011183:Postoperative Complications; D012189:Retrospective Studies; D016896:Treatment Outcome
D019382:Human Growth Hormone